Suppr超能文献

可调节人工晶状体的益处与障碍

Benefits and barriers of accommodating intraocular lenses.

作者信息

Pepose Jay S, Burke Joshua, Qazi Mujtaba A

机构信息

aPepose Vision Institute, Chesterfield bDepartment of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Curr Opin Ophthalmol. 2017 Jan;28(1):3-8. doi: 10.1097/ICU.0000000000000323.

Abstract

PURPOSE OF REVIEW

Presbyopia and cataract development are changes that ubiquitously affect the aging population. Considerable effort has been made in the development of intraocular lenses (IOLs) that allow correction of presbyopia postoperatively. The purpose of this review is to examine the benefits and barriers of accommodating IOLs, with a focus on emerging technologies.

RECENT FINDINGS

True accommodation of an IOL involves a dynamic increase in dioptric power to affect a shift from distance to intermediate or near focus. The Crystalens (Crystalens Bausch and Lomb, Inc., Rochester, NY, USA) was the first IOL labeled by the FDA as an accommodating IOL. Further studies have suggested that the Crystalens and several other single optic presbyopia-correcting IOLs may be providing improved intermediate or near vision predominantly through pseudoaccommodative mechanisms, in addition to small changes in axial translation. In light of these findings, a more objective demonstration of accommodation is now required for an IOL to have an accommodative label. Newer technology accommodating IOLs in development have embraced design strategies using dual optics, shape-changing optics, and IOLs with dynamic changes in refractive index. Prevention and treatment algorithms for capsular contraction syndromes unique to Crystalens and Trulign IOL designs will be discussed.

SUMMARY

Accommodating IOLs that are in current use are constrained by their low and varied amplitude of accommodation. Such limitations may be circumvented in the future by accommodative design strategies that rely more on shape-related changes in the surfaces of the IOLs or in dynamic changes in refractive index than by forward translation alone.

摘要

综述目的

老花眼和白内障的发展是普遍影响老年人群的变化。在开发能够在术后矫正老花眼的人工晶状体(IOL)方面已经付出了巨大努力。本综述的目的是研究可调节人工晶状体的益处和障碍,重点关注新兴技术。

最新发现

人工晶状体的真正调节涉及屈光力的动态增加,以实现从远距离到中距离或近距离焦点的转换。美国眼力健公司(位于纽约州罗切斯特)生产的晶状体内植入物是首个被美国食品药品监督管理局(FDA)标记为可调节人工晶状体的产品。进一步的研究表明,除了轴向平移的微小变化外,晶状体内植入物和其他几种单光学区老花眼矫正人工晶状体可能主要通过假调节机制改善中距离或近距离视力。鉴于这些发现,现在人工晶状体若要有调节标签,需要更客观地证明其调节能力。正在研发的新型可调节人工晶状体采用了双光学区、形状改变光学区以及折射率动态变化的人工晶状体等设计策略。还将讨论针对晶状体内植入物和Trulign人工晶状体设计所特有的囊袋收缩综合征的预防和治疗算法。

总结

目前使用的可调节人工晶状体受到其低且变化的调节幅度的限制。未来,可调节人工晶状体的设计策略可能更多地依赖于人工晶状体表面与形状相关的变化或折射率的动态变化,而非仅仅依靠向前平移,从而规避这些限制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验